RLD2203
- Generic Name
- RLD2203
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 40
- Registration Number
- NCT05548387
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 40
- Registration Number
- NCT05548543
- Locations
- 🇰🇷
Jeonbuk University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 24
- Registration Number
- NCT05481307
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath